IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB)

    loading  Checking for direct PDF access through Ovid



TAF has shown less bone and renal effects with similar efficacy rates compared to TDF in Phase 3 studies after 96 weeks of double-blind (DB) treatment. We evaluated patients who completed 96 weeks of DB treatment with TAF or TDF and switched to open label (OL) treatment with TAF, including those with 1 year of data (through Week 144) to determine changes in bone mineral density (BMD), creatinine clearance (CrCL), and the maintenance of viral suppression.


1298 CHB patients who were HBeAg-negative or HBeAg-positive were randomised and treated with TAF or TDF. At Week 96, 541 (42%; TAF 361; TDF 180) patients had completed DB treatment with TAF or TDF and switched to OL TAF. Analyses included subjects with values at Week 96 and at Week 144 for creatinine clearance (n=401), spine BMD (n=288) or hip BMD (n=287), HBV DNA (n=394) and ALT normalisation by AASLD criteria (n=398).


CrCL improved in patients who switched from DB TDF to OL TAF at Week 144 compared to Week 96 (n=122, median (Q1, Q3) change=+3.6 (-4.2,+8.4) ml/min, p<0.001); (figure 1 and 2b ). (HBV DNA <29 IU/mL) were maintained in both treatment groups at Week 144 (TDF 87% vs 88% and TAF 91% vs 89%). One year after switching the rate of ALT normalisation increased in the TDF group relative to Week 96 (n=122; 65% vs 47%; p<0.001) and did not differ from the TAF group (65% vs 66%; p=0.83) at Week 144.


Patients who switched from TDF to TAF demonstrated continued improvements in BMD and CrCL over 48 weeks of treatment, virologic control was maintained, and rates of ALT normalisation increased.

Related Topics

    loading  Loading Related Articles